《中国康复理论与实践》

《中国康复理论与实践》 ›› 2005, Vol. 11 ›› Issue (06): 429-430.

• 专题 • 上一篇    下一篇

伴糖尿病及高血压的不稳定型心绞痛患者介入治疗后替米沙坦对血浆炎症因子水平的影响

彭晓玲; 林泽鹏; 刘强; 李忠红; 金光临; 张志伟; 蔡乃绳   

  1. 1.深圳市孙逸仙心血管医院心內科 广东深圳市 518020;2.上海医科大学附属中山医院心内科 上海市 518020
  • 收稿日期:2004-12-13 出版日期:2005-06-25 发布日期:2005-06-25

Effect of telmisartan on plasma levels of inflammatory cytokine in unstable angina patients complicated with diabetes mellitus and hypertensive after percutaneous coronary intervention

PENG Xiao-ling, LIN Ze-peng, LIU Qiang, et al   

  1. The Department of Cardiology, Sun Yat-sen Cardiovascular Hospital, Shenzhen 518020, Guangdong, China
  • Received:2004-12-13 Published:2005-06-25 Online:2005-06-25

PDF (PC)

被引次数

3

摘要： 目的探讨伴糖尿病及高血压的不稳定型心绞痛患者在冠状动脉介入治疗后,过氧化物酶体增殖物活化受体γ(PPARγ)激动剂替米沙坦对血浆炎症因子水平的影响。方法50例伴糖尿病及高血压的不稳定型心绞痛患者在冠状动脉介入治疗后,被随机分为口服试验组(替米沙坦组,n=25)和对照组(培垛普利组,n=25),随访6个月,用酶联免疫吸附法测定患者在介入治疗前和治疗后6个月的血浆C-反应蛋白(CRP)、巨噬细胞炎症蛋白-1(MCP-1)水平,并观察血糖、胰岛素水平、胰岛素抵抗指数及血脂的变化。结果治疗6个月后,试验组患者CRP及MCP-1明显下降(P<0.01),且降低幅度与血糖水平呈明显负相关(P<0.01),空腹血糖、血清胰岛素及胰岛素抵抗指数亦降低(P<0.05);对照组患者CRP及MCP-1降低(P<0.05),其他指标无明显变化;试验组患者心血管事件发生率明显下降(P<0.01)。结论替米沙坦在提高胰岛素敏感性、改善糖代谢的同时,能降低伴糖尿病及高血压的不稳定型心绞痛患者血浆CRP、MCP-1水平以及心血管事件的发生率。

关键词: 冠心病, 替米沙坦, 过氧化物酶体增殖物活化受体γ, 糖尿病, C-反应蛋白, 巨噬细胞炎症蛋白-1

Abstract: ObjectiveTo observe the effect of telmisartan on plasma levels of inflammatory cytokine in coronary artery disease (CAD) patients complicated with diabetes mellitus and hypertension after percutaneous coronary intervention.MethodsFifty CAD patients who just had undertook angioplasty and implanted stents were randomly divided into two groups, the test group (telmisartan group, n=25) and control group (perindopril group, n=25). After treatment, patients were followed-up for 6 months; plasma samples were collected from each patient before and after percutaneous coronary intervention. Then plasma levels of C-reactive protein (CRP), monocyte chemoattractant protein-1 (MCP-1) were measured by enzyme-linked immunoassay. The changes of cholesterol, fasting plasma glucose (FPG), insulin and insulin resistance index (IRI) were observed.ResultsAt the end of 6 months, plasma levels of CRP and MCP-1 of patients in the test group significantly declined (P<0.01), and showing a inversely correlation with FPG (P<0.01), and FPG, insulin and IRI also declined. In the control group, only CRP and MCP-1 declined (P<0.05). Meanwhile, the frequency of cardiovascular events in test group was significantly lower than that in the control group.ConclusionTelmisartan can decline plasma levels of CRP, MCP-1 and frequency of cardiovascular events as well as increasing insulin sensitivity and improving glucose metabolism to unstable angina patients.

Key words: coronary artery disease, telmisartan, peroxisome proliferator-activators receptor γ, diabetes mellitus, C-reactive protein (CRP), monocyte heemoattractant protein-1 (MCP-1)